Compare BLTE & WAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLTE | WAY |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.0B |
| IPO Year | 2021 | 2023 |
| Metric | BLTE | WAY |
|---|---|---|
| Price | $137.18 | $19.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | ★ $198.00 | $36.59 |
| AVG Volume (30 Days) | 104.2K | ★ 2.6M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 569.23 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $1,099,278,000.00 |
| Revenue This Year | N/A | $18.26 |
| Revenue Next Year | $492.11 | $10.62 |
| P/E Ratio | ★ N/A | $88.36 |
| Revenue Growth | N/A | ★ 16.50 |
| 52 Week Low | $56.68 | $18.02 |
| 52 Week High | $200.00 | $41.30 |
| Indicator | BLTE | WAY |
|---|---|---|
| Relative Strength Index (RSI) | 31.51 | 40.84 |
| Support Level | $103.94 | N/A |
| Resistance Level | $172.02 | $26.73 |
| Average True Range (ATR) | 7.11 | 0.88 |
| MACD | -1.16 | -0.01 |
| Stochastic Oscillator | 7.06 | 43.03 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. Its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.